Travere Therapeutics, Inc. (TVTX) Stock Price & How to Invest

Travere Therapeutics (Nasdaq: TVTX) develops and sells treatments for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is a once-daily oral dual endothelin and angiotensin receptor antagonist that received full FDA approval for IgA nephropathy in September 2024 and, in April 2026, became the first FDA-approved therapy specifically for focal segmental glomerulosclerosis (FSGS). The company also sells THIOLA and THIOLA EC (tiopronin) for cystinuria, a small but steady legacy franchise, and partners FILSPARI outside the US with CSL Vifor in Europe and Everest Medicines in parts of Asia. Behind the commercial business sits a nephrology and metabolic pipeline led by pegtibatinase for classical homocystinuria and the in-licensed BTK inhibitor civorebrutinib for immune-mediated kidney diseases including primary membranous nephropathy.

The investment picture is unusually concentrated. In the second quarter of 2026 Travere reported total revenue of ~$169.6 million, of which FILSPARI US net sales were ~$141.1 million, up ~96% year over year, on 2,012 new patient start forms across both indications. Gross margin runs above 98%, so essentially every incremental sales dollar flows toward covering an operating base of roughly $60 million of quarterly R&D and $96 million of SG&A. Total revenue grew about 48% year over year, though earnings per share of about -$0.10 came in below what analysts had expected. The company is not yet GAAP profitable (a ~$34.8 million net loss in the quarter and about $68 million over the trailing twelve months), but operating cash flow is positive at roughly $93 million over the trailing year, and cash plus marketable securities stood at ~$489 million against ~$617 million of mostly convertible debt.

Several things have happened since. On September 21, 2026 Travere announced that Eric Dube will step down as president and CEO to focus on his health and family, with Bradley L. Campbell, who spent nearly 20 years at Amicus Therapeutics and ran it from 2022 until its sale to BioMarin, taking over on December 1, 2026; Dube stays on as an executive advisor through February 15, 2027. Two days later the company received a US patent notice of allowance covering methods of using FILSPARI in FSGS, and in October it said it would present new FILSPARI data in IgAN and FSGS at ASN Kidney Week 2026. Insiders sold shares in September, including one sale of about $25.4 million. The stock closed near $50.19 on October 16, 2026, up about 27% year to date and 82% over one year but down about 20% over the past month, for a market value near $4.7 billion. Third-quarter results are expected around October 29, 2026, with consensus near $196 million of revenue. What an owner is really underwriting is durability: whether FILSPARI's dual-mechanism label and first-mover FSGS position hold up against Novartis, Otsuka and Vera Therapeutics, all of whom now have approved IgAN drugs of their own.

Single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. The IgA nephropathy field got crowded quickly, with Novartis marketing both VANRAFIA (atrasentan) and FABHALTA (iptacopan), Otsuka selling TARPEYO and Voyxact, and Vera Therapeutics winning approval for Trutakna (atacicept), and FILSPARI carries a REMS program and a boxed warning for hepatotoxicity and embryo-fetal toxicity that at least one rival endothelin blocker does not. Regulatory timing has already proven volatile for this stock: shares fell more than 30% in January 2026 when the FDA extended the FSGS review, and several plaintiff law firms opened securities investigations afterward, though the application was subsequently approved. The balance sheet carries more debt (~$617 million, largely convertible) than cash (~$489 million), so continued losses would eventually mean dilution or refinancing. A CEO transition in the middle of a two-indication launch adds execution risk, and the stock fell about 20% in the month to mid-October 2026 as insiders sold shares and the new FILSPARI data drew a muted reaction. Finally, pegtibatinase data is more than a year out, which leaves little to cushion a disappointment in the commercial franchise before then.

14 analysts publish price targets on TVTX, averaging $75.21 against a $49.16 price as of November 2026, or +53.0%. The published targets run from $62.00 to $90.00, a moderate spread, and the ratings split 14 buy, 1 hold, 0 sell. Over the last six months there have been 10 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TVTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Travere Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The FSGS launch, a market with no prior approved therapy. FSGS is the second indication and the cleaner competitive setup, because until April 2026 no drug was approved for it at all. The most optimistic published target, $90.00, assumes this works close to its best case.

The case against. Single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. The most pessimistic target, $62.00, is roughly what TVTX is worth if this bites instead.

Read the full bull and bear case on TVTX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Travere Therapeutics, Inc. (TVTX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Travere Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$591M; Q2 2026 total revenue up ~48% year over year
• Q2 2026 revenue: ~$169.6M total, with FILSPARI US net sales of ~$141.1M (+96% YoY)
• Net income (TTM): ~-$68M net loss (~$0.74 loss per share); Q2 GAAP loss ~$34.8M
• Operating cash flow (TTM): ~$93M
• Cash and debt: ~$489M cash and marketable securities vs ~$617M total debt (net debt ~$128M)
• Market cap: ~$4.7B, roughly 7.9x trailing sales, at ~$50 a share
• Forward P/E (2027 consensus EPS): ~9x

There is no meaningful trailing P/E here because Travere is still running a small net loss, so the market is valuing it on the revenue trajectory and on how close FILSPARI gets to the stated $3B-plus peak ambition; on analysts' 2027 EPS estimate of about $5.64 the forward multiple is near 9. The stock has moved violently in both directions over the past year, with a 52-week range of roughly $22.59 to $68.73, which tells you how much of the price is regulatory and launch expectation rather than trailing results. At about 7.9x sales with revenue still growing near 50%, the multiple is not extreme for a growth biotech but it does assume the launch curve holds.

Other names that sit close to TVTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get TVTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TVTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TVTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Travere is a one-product commercial story with real, fast-growing revenue and a differentiated label, priced at roughly eight times trailing sales on the assumption that the FSGS launch keeps compounding, with a new CEO taking over in December 2026.

Whether TVTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TVTX a buy or a sell?, and where the stock could go from here in the TVTX stock forecast.

For income investors, whether TVTX pays a dividend and how the payout looks is covered in does TVTX pay a dividend? And to weigh TVTX against a peer, read the full side-by-side comparisons: TVTX vs NVS and TVTX vs VERA.